Back to search

Article

Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemia

2024-04-04

Abstract excerpt

BCL-2 was the first gene identified to have antiapoptotic effects and venetoclax is an oral selective BCL-2 inhibitor, which has great potential in the treatment of patients with acute myeloid leukemia (AML) who are not candidates for intensive therapy. Notably, posaconazole, an oral antifungal drug, is also a strong factor that can affect blood venetoclax concentrations. To the best of our knowledge, the relation...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0f5b650d-64c8-5065-a775-a2cc219103d9
DOI
10.21203/rs.3.rs-4188474/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemiaDOI 10.21203/rs.3.rs-4188474/v1
Targeting Bcl-2 Proteins in Acute Myeloid LeukemiaSemantic proximity
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study.Semantic proximity
Mechanisms of venetoclax resistance and solutionsSemantic proximity
Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity
Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.Semantic proximity
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective studySemantic proximity
Venetoclax resistance: mechanistic insights and future strategiesSemantic proximity
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity
Select a neighboring publication to make it the new centre.